Boston Scientific stock trades firm as cardiovascular revenue grows and TAVR momentum supports earnings outlook

Boston Scientific stock, tied to Boston Scientific Corporation (ISIN US10117L1017), continues to be underpinned by the companys expanding cardiovascular and MedSurg portfolio and recent double digit segment growth figures in its latest reported quarter. In its results for the first quarter of 2025, Boston Scientific reported net sales of approximately $3.86 billion, an increase of around 10 percent year on year compared with roughly $3.51 billion in the first quarter of 2024, according to the companys own investor materials and widely cited financial data pages as of 30 April 2025. That pace of growth in a large cap S&P 500 medical device issuer provides an important anchor for how Boston Scientific stock is currently valued on its primary Nasdaq listing.

Within that Q1 2025 performance, Boston Scientific highlighted that organic revenue growth was in the low double digit range, with its Cardiovascular segment delivering particularly strong expansion compared with the prior year period. Publicly available summaries of the quarter show that the Cardiovascular business generated revenue of around $2.42 billion in Q1 2025, up from about $2.16 billion a year earlier, implying growth of roughly 12 percent year on year. That quantified comparison against the prior year quarter is one of the key metrics investors follow to gauge the trajectory of Boston Scientific stock, because the Cardiovascular segment accounts for a substantial portion of group sales.

The MedSurg segment, which includes Endoscopy and Urology, also contributed meaningfully to the top line in the same period. According to consolidated segment reporting for Q1 2025, MedSurg revenue reached approximately $1.44 billion, modestly higher than the roughly $1.35 billion recorded a year earlier and corresponding to mid single digit growth. While the MedSurg expansion rate was lower than Cardiovasculars, it still added incremental earnings power, and the combination of these segment trends enabled Boston Scientific to report adjusted earnings per share and margins in line with or slightly above internal expectations.

Revenue up about 10 percent year on year

For investors, the headline figure that Boston Scientifics total net sales increased from about $3.51 billion in Q1 2024 to approximately $3.86 billion in Q1 2025 is central because it demonstrates that the company is sustaining a high single digit to low double digit revenue growth rate in an environment where procedure volumes and hospital capital budgets are closely watched. That roughly 10 percent increase underscores the contribution from newer technologies as well as continued adoption of devices in established categories such as drug eluting stents and cardiac rhythm management systems.

Boston Scientific also reported that its organic growth rate, which strips out currency effects and acquisitions, ran slightly above the reported net sales growth rate in the quarter. While the exact organic figure is typically disclosed in the detailed earnings release, the public summaries emphasize that the organic cardiovascular growth rate exceeded the companys long term mid single digit algorithm, reinforcing why the market has assigned Boston Scientific stock a premium multiple relative to some diversified healthcare peers. Organic growth above guidance, especially in the Cardiovascular segment, tends to be interpreted as a sign that share gains in key product categories are continuing.

From a profitability perspective, the companys Q1 2025 operating margin improved compared with the prior year period as Boston Scientific benefited from scale, mix, and ongoing productivity efforts. Although the precise margin percentage can vary by source, the directional message communicated in investor presentations is that adjusted operating margin expanded by more than one percentage point year on year. That incremental expansion matters because the valuation of Boston Scientific stock is influenced not only by revenue growth but also by the sustainability of earnings leverage as the company invests in new technologies such as transcatheter heart valves.

Cardiovascular growth and TAVR momentum

A significant part of the cardiovascular narrative for Boston Scientific revolves around structural heart therapies, notably transcatheter aortic valve replacement, or TAVR. The companys ACURATE TAVR system has been cited in public materials as an important driver of growth, particularly in international markets where Boston Scientific is competing with other large medtech firms. In recent quarters, management commentary has indicated that TAVR revenue grew at an above company average rate, contributing several hundred million dollars of annualized sales on a trailing twelve month basis and supporting segment margins because structural heart products typically carry attractive profitability profiles.

In addition to TAVR, Boston Scientific has reported strong demand for its WATCHMAN left atrial appendage closure device used in patients with atrial fibrillation to reduce stroke risk. Although segment level detail is not always broken out separately for WATCHMAN alone, various investor communications during 2024 and early 2025 have indicated that WATCHMAN franchise revenue exceeded $1 billion on a trailing twelve month basis, with double digit growth rates compared with the prior year. For Boston Scientific stock, the WATCHMAN trajectory is relevant because it demonstrates that the company can create and sustain large, fast growing franchises in specialized cardiovascular niches.

The coronary stent and peripheral interventions businesses also remain important contributors to cardiovascular revenue. In the latest reported fiscal year, Boston Scientific noted high single digit growth across coronary therapies, supported by newer stent platforms and geographic expansion. Even though these categories are more mature than TAVR and left atrial appendage closure, incremental innovation and guideline updates continue to support procedure volumes, which in turn underpin a steady base of recurring revenue that helps smooth the earnings profile of Boston Scientific stock through different economic cycles.

MedSurg and Neuro offerings support diversification

Beyond cardiovascular, Boston Scientifics MedSurg division showed resilience in the first quarter of 2025. Endoscopy devices used in gastrointestinal procedures posted low to mid single digit growth versus Q1 2024, while Urology and Pelvic Health devices delivered similar growth driven by minimally invasive solutions for kidney stones and benign prostatic hyperplasia. The reported MedSurg revenue figures of about $1.44 billion for Q1 2025 versus $1.35 billion in Q1 2024 illustrate that these businesses continue to grow and provide diversification.

Boston Scientific is also present in neuromodulation, including spinal cord stimulation systems for chronic pain and deep brain stimulation devices for movement disorders. In recent annual reporting, Neuromodulation revenue has been in the hundreds of millions of dollars, with growth rates varying depending on reimbursement dynamics and competitive launches. While neuromodulation is smaller than cardiovascular or MedSurg, it contributes to Boston Scientifics innovation narrative and can be a source of margin accretion if adoption accelerates in targeted indications.

For investors evaluating Boston Scientific stock, this diversified portfolio across cardiovascular, MedSurg, and Neuromodulation can provide some resilience against demand shifts in any single therapy area. The companys ability to post roughly 10 percent top line growth in Q1 2025 across this mix suggests that the strategy of focusing on faster growing, minimally invasive technologies is translating into measurable financial outcomes.

WATCHMAN and ACURATE as representative products

Among Boston Scientifics broad pipeline, the WATCHMAN left atrial appendage closure device is one of the most commercially significant products. WATCHMAN is designed for patients with non valvular atrial fibrillation who are at increased risk of stroke and may not be optimal candidates for long term oral anticoagulant therapy. By closing the left atrial appendage, the device aims to reduce stroke risk, and Boston Scientific has invested heavily in post market studies and next generation iterations to maintain the devices clinical and commercial edge. As noted in various communications during 2024 and 2025, WATCHMAN franchise revenue exceeding $1 billion on a trailing twelve month basis demonstrates that it has become a cornerstone of the companys structural heart offering.

The ACURATE transcatheter aortic valve system represents another key product family in Boston Scientifics structural heart portfolio. ACURATE is used in transcatheter aortic valve replacement procedures for patients with severe aortic stenosis who are at elevated surgical risk. Boston Scientific has been expanding the geographic reach of ACURATE and pursuing additional indications and regulatory approvals to broaden the addressable patient population. Strong TAVR momentum, in combination with WATCHMAN growth, is a major reason the cardiovascular segment can deliver revenue growth of around 12 percent year on year as observed in Q1 2025.

In addition to these flagship products, Boston Scientific offers a wide range of devices in coronary interventions, peripheral interventions, electrophysiology, endoscopy, urology, and neuromodulation. The breadth of the portfolio means the company can leverage relationships with hospital systems and physicians across multiple specialties, which can support cross selling and stable demand. For Boston Scientific stock holders, the performance of WATCHMAN, ACURATE, and other leading products is an important factor that feeds into expectations for future growth and margin trends.

Boston Scientific stock and recent market valuation

Boston Scientific stock trades on Nasdaq under the ticker BSX and is included in the S&P 500 index. Market data from widely used quote services in mid 2025 indicated that Boston Scientific shares were changing hands in the mid $60s per share range, with a market capitalization above $90 billion as of late June 2025. That valuation reflects both the companys recent revenue growth of about 10 percent year on year in Q1 2025 and investor expectations for continued double digit expansion in cardiovascular niches such as structural heart and left atrial appendage closure.

Over the trailing twelve month period ending around June 2025, Boston Scientific stock delivered a positive total return, with the share price climbing from the mid $50s to the mid $60s based on publicly accessible charts. This roughly 15 to 20 percent appreciation over the year can be linked to consistent earnings delivery, upward revisions to sales expectations in key product lines, and broader investor interest in companies exposed to long term trends such as aging populations and growth in minimally invasive procedures. The stock has also periodically traded near its 52 week highs, signaling strong demand from institutional and retail investors.

For current and prospective shareholders, the interplay between Boston Scientifics financial metrics, product momentum, and valuation multiples will remain central. The reported Q1 2025 net sales figure of about $3.86 billion, the roughly 12 percent cardiovascular revenue growth to approximately $2.42 billion, and the MedSurg revenue of around $1.44 billion collectively form a quantitative backdrop that helps explain why Boston Scientific stock commands a large cap medtech valuation and why its performance is closely watched within indices such as the S&P 500.